Understanding PCOS symptoms: which signs and blood values are relevant

What to expect in this article

1. What PCOS is—and why the name is changing now
2. How common PCOS is and how many people do not know they have it
3. Which PCOS symptoms stand out together
4. How the diagnosis is made: two of three criteria
5. Which blood values are part of the androgen profile
6. Two persistent misconceptions
7. Values that do not establish a diagnosis but rule things out
8. Why ultrasound and AMH appear side by side
9. The three criteria side by side
10. When something needs to be clarified without taking a detour
11. What an at-home hormone test contributes
12. What ultimately matters
Frequently asked questions

1. What PCOS is—and why the name is changing now

PCOS stands for polycystic ovary syndrome, also called polycystic ovarian syndrome in German. The name describes what stood out most to the medical community decades ago: the appearance of the ovaries on ultrasound. It poorly describes what the condition is really about. It refers to an interplay of disrupted ovulation patterns, an excess of male hormones, and a metabolic state connected to them.

That is precisely why the name was changed. The patient guideline for AWMF registry number 089-004, dated June 2026, states that the condition was renamed internationally in May 2026: from “Polycystic Ovary Syndrome” (PCOS) to “Polyendocrine Metabolic Ovarian Syndrome” (PMOS). The new name brings the hormonal and metabolic aspects to the forefront and removes cysts from the title.

This text nevertheless continues to use PCOS. That is the term people search for and that is used in documentation; it also appears in the medical version of the same guideline from June 2025 and in the World Health Organization fact sheet dated January 22, 2026. If you come across the new name: it refers to the same condition.

A syndrome is not a single finding

A syndrome is a pattern. It is not identified through a single measurement, but through the combination of several features and the question of whether something else is causing the same signs.

The patient guideline essentially says this itself: There is still no specific test that can establish the diagnosis with certainty. Immediately afterward, it states that other conditions that can cause similar symptoms should instead be ruled out. Without this second half, the sentence sounds as though PCOS cannot be detected at all.

2. How common PCOS is and how many people do not know they have it

PCOS is not a rare condition. In its fact sheet dated January 22, 2026, the World Health Organization states how many women of reproductive age are affected. The second figure is more interesting: the share of those whom no one ever examined for it.

PCOS in numbers

Sources: World Health Organization, fact sheet “Polycystic ovary syndrome,” as of January 22, 2026; AWMF registration number 089-004, S2k guideline, as of June 2025. The reviewed sources do not provide a reliable prevalence figure specifically for Germany.

The second number explains why this article is necessary. When a large proportion of those affected do not know about the diagnosis, it is rarely because nobody had symptoms. It is because the signs seem unremarkable when viewed individually: An irregular cycle is dismissed as the body being temperamental, and acne as a skin issue. Only side by side do they form a pattern.

The third number is the only one you can track yourself. Recording cycle lengths costs nothing and provides information that no laboratory analysis can.

3. Which PCOS symptoms stand out together

In 2026, the World Health Organization lists the following signs: irregular, unpredictable, or absent bleeding; for some, also heavy, prolonged, or painful bleeding; increased facial or body hair; male-pattern hair loss or thinning scalp hair; and acne or oily skin. The patient guideline for AWMF 089-004 names the same features in clinical language: androgenetic alopecia, acne, hirsutism, and cycles longer than 35 days.

The cycle is the loudest sign and the easiest one to overlook

A shifting cycle becomes a habit. Anyone who has not known for years when their next period will come eventually stops finding it unusual. The guideline draws a line here: oligo- or anovulation, meaning infrequent or absent ovulation, is primarily identified clinically by a menstrual cycle disorder.

What “repeatedly” means in this context is determined by medical assessment, not by a single unusual month. The relevant figures are shown in the number strip above.

Skin and hair are part of the picture, but they are not proof on their own

Excess body hair, acne, and thinning scalp hair are visible signs of androgen excess. In practice, they are assessed according to established standards: hirsutism using the modified Ferriman–Gallwey score, acne according to dermatological criteria, and hair loss using the Ludwig score. This is broadly in line with Recommendations 1.2.4 to 1.2.6 of the S2k guideline. This is an examination, not a self-assessment in front of the mirror.

The same skin signs can have many causes. What hormones generally have to do with the appearance of the skin, regardless of a named condition, is covered in the article Hormones and skin appearance: what is connected. Here, the focus is on a named condition in which the skin is one of several signs.

One more distinction is important, because otherwise the two can blur together: PCOS involves an excess of androgens, meaning male hormones. This is the opposite direction from estrogen dominance, where an excess on the estrogen side is at issue. Those looking for this other pattern will find the right information in estrogen dominance and its values. The two patterns are regularly confused.

4. How the diagnosis is made: two of three criteria

The basis is older than many people assume: a 2003 consensus developed by the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group and published in Human Reproduction in 2004. The German S2k guideline uses the modified version, in which anti-Müllerian hormone is accepted as an alternative to the ultrasound finding.

The three criteria are worded as follows in the same recommendation: “1. Clinical and/or biochemical hyperandrogenism 2. Ovulatory dysfunction 3. Polycystic ovarian morphology (PCOM) and/or high AMH concentration and exclusion of relevant differential diagnoses”.

The final half-sentence is often omitted, and the meaning then changes. It is not a footnote but a condition. Two fulfilled criteria are sufficient only if it has also been checked that nothing else is causing the same signs. What this means is explained in Chapter 7.

“Clinical and/or biochemical hyperandrogenism” means visible signs of androgen excess or elevated androgen levels in the blood. Either one is sufficient for this criterion. “Ovulatory dysfunction” means a disturbed ovulation cycle, while “polycystic ovarian morphology” refers to the characteristic appearance of the ovaries on ultrasound.

The structure leads to something that is often overlooked: there is no ranking and no primary finding. Any two of the three criteria support the diagnosis, and the combination varies from patient to patient. The guideline group also emphasizes that diagnosis and care when PCOS is suspected should be interdisciplinary; this is stated in substance in Recommendation 1.1.1.

5. Which blood values are part of the androgen profile

For biochemical hyperandrogenism, Recommendation 1.2.7 of the guideline lists three values first: total testosterone, SHBG, and the free androgen index calculated from them. It also mentions DHEA-S and androstenedione, but as secondary tests. They provide little additional information and are mainly used to rule out other conditions.

Why three values instead of one? Because most testosterone in the blood is bound. SHBG is the transport protein that binds it: when more of it is present, less testosterone is mathematically available in free form, even when the total level remains the same. The free androgen index relates the two values to each other. How this calculation works and what an SHBG level means on its own are explained in the articles Free androgen index: how it is calculated and SHBG level: what it means.

Numbers this article intentionally does not provide

You will not find a reference range for testosterone, free testosterone, or the free androgen index here. This is not an oversight. The reviewed concise version of the S2k guideline AWMF 089-004 (2025) names the parameters but does not establish absolute values for diagnosing PCOS. A number we cannot substantiate does not belong in a text that someone takes to their medical appointment.

In practice, this means that a testosterone level outside the laboratory reference range may indicate an androgen excess. It does not establish one. And a level within the range rules nothing out, because the visible signs alone may also fulfill the criterion. The general interpretation of fluctuating levels is covered under hormonal imbalance and its symptoms.

Two points are often handled differently than the guideline recommends. In recommendation 1.3.2, it advises against determining the HOMA index and comparable insulin resistance parameters outside studies. And although the glucose tolerance test, HbA1c, and fasting glucose are included in the guideline (recommendation 2.2.1), they are not used for diagnosis. They are part of risk screening.

6. Two persistent misconceptions

Both statements come up in forums and in people’s recollections of a half-understood conversation. Both lead women to believe they have been fully evaluated when they have not.

Checked against the evidence

Both corrections lead to the same conclusion: away from searching for the one feature that decides the question. It does not exist, neither in the ultrasound image nor in a calculation based on two hormone levels.

7. Values that do not establish a diagnosis but rule things out

Anyone who finds a list of “PCOS blood tests” online will usually see a dozen parameters side by side, as if they all pointed in the same direction. They do not. Many of these values appear in the guideline under differential diagnosis and are intended to rule out other conditions that can cause the same signs.

In recommendation 1.2.14, the S2k guideline assigns an examination to each condition that must be ruled out. Prolactin is used to rule out a prolactinoma, a benign tumor of the pituitary gland. TSH and fT4 take the thyroid out of the running. 17-α-hydroxyprogesterone, supplemented with an ACTH test when necessary, is used to identify non-classic congenital adrenal hyperplasia, an inherited disorder of the adrenal cortex.

The list continues with FSH, which rules out primary ovarian insufficiency. Cortisol, ACTH, and the 1-mg dexamethasone suppression test target Cushing syndrome, meaning persistent cortisol excess; the suppression test also targets androgen-secreting tumors. And beta-hCG rules out pregnancy.

The difference is not mere semantics. An unremarkable prolactin level says nothing about PCOS; it only means that a prolactinoma has become a less likely explanation. A normal TSH does not establish PCOS; it rules out a thyroid disorder. These values work from the reverse direction: they eliminate possible explanations until the remaining constellation fits.

This is precisely where the limits of any laboratory test without medical guidance become apparent. A value that falls outside the normal range changes the clinical question, and the next examination is often quite different from what was expected. No self-test can take this chain of events into account.

8. Why ultrasound and AMH appear side by side

The third criterion is the only one for which the German guideline allows a laboratory value as an alternative to an examination. A high concentration of anti-Müllerian hormone may be used instead of the ultrasound finding. That is the modified part of the modified Rotterdam definition.

The guideline formulates this in two recommendations that must be read together. Recommendation 1.2.11 states: “The AMH concentration can be used as a surrogate parameter for PCOM.” A surrogate parameter is a substitute value that takes the place of a quantity that is difficult to determine. Recommendation 1.2.12 states: “Anti-Müllerian hormone (AMH) should currently not be used as the sole criterion for diagnosing PCOS.”

Anyone who quotes only the second sentence turns AMH into a worthless value. Anyone who quotes only the first turns it into a substitute for everything. The truth lies in between: AMH can take the place of the ultrasound finding, but not the diagnosis. A high AMH value fulfills one of the three criteria, and at least two are necessary.

An AMH value from a laboratory is therefore information, not a result. It replaces neither the conversation about the menstrual cycle nor the assessment of visible signs nor the exclusion described in Chapter 7.

9. The three criteria side by side

The same three criteria, this time organized around the same questions: What is the criterion based on, who establishes it, what can a blood test contribute, and what can it not contribute?

The half-sentence that Recommendation 1.2.1 mentions together with the criteria appears above all three lines: “and exclusion of relevant differential diagnoses.” A table in which two lines apply does not replace it.

10. When something needs to be clarified without taking a detour

There is one situation in this topic where waiting and doing your own research are not appropriate. The S2k guideline states it in recommendation 2.7.1 in one sentence: “Abnormal uterine bleeding must be evaluated in every case.” (AWMF 089-004, German Society for Endocrinology, status June 2025)

“Abnormal” here means unusual for you. Bleeding outside your usual pattern, unusually heavy or prolonged bleeding, or bleeding after a longer pause. The patient version of the same guideline conveys the same point in everyday language. This is not a recommendation left to discretion, but an “in every case” requirement.

The background, without a number: In 2026, the World Health Organization described that irregular or infrequent bleeding in women with PCOS may increase the risk of endometrial hyperplasia, meaning thickening of the uterine lining, and endometrial cancer. A specific risk figure could not be confirmed precisely in the sources reviewed, so none is given here.

The World Health Organization also notes that early medical support can help women protect their health and well-being during and beyond their reproductive years. Early is better than late.

11. What an at-home hormone test contributes

The honest answer is brief: An at-home test gives you numbers. It does not give you an answer to the question you came with. People who search for “PCOS symptoms” usually want to know whether they have it, and no blood sample can clarify that. Diagnosis involves medical evaluation, usually imaging, and ruling out other conditions.

What numbers can still do: They change the conversation. Anyone who comes to an appointment with recorded cycle lengths from six months and a few hormone levels is no longer describing a vague feeling, but presenting something concrete. Preparation, not a final decision.

From the mybody®x (MYBODY Lab GmbH) range, the Menopause Check | Menopause Hormone Test costs €159.00 and measures eight hormone levels from a blood sample, including testosterone, SHBG, DHEA-S, FSH, LH, and TSH. This covers some of the parameters discussed in this article. It does not diagnose or rule out anything. It does not include AMH, does not replace an ultrasound, and is not designed as a PCOS test, but to assess the hormonal situation during menopause. It is a starting point for a conversation, and it requires the recorded cycle day because otherwise FSH and LH are difficult to interpret. Price as of August 29, 2026; subject to change.

More important than choosing a test is what happens afterward. An abnormal result should be discussed, while an unremarkable result proves nothing. Both apply more strongly here than to almost any other laboratory topic because two of the three criteria are not found in the blood at all.

12. What ultimately matters

It began with the observation that PCOS rarely manifests through a single sign. The reverse is also true: A single sign cannot rule it out either. A normal testosterone level, an unremarkable ultrasound, or a cycle that was on time during those six months—none of these alone answers anything.

What you can take away is less than you hoped for and more than it may seem at first. You can name the three criteria and distinguish which values contribute to the overall picture and which merely rule out other conditions. The statement “your values are normal” is therefore not yet an answer to your question.

The specific next step costs nothing: For six months, note when your bleeding begins. This is the one piece of information that no laboratory in the world can generate for you, and it factors into two of the three criteria. If something happens in between that is unfamiliar to you, follow the sentence from Chapter 10.

Frequently asked questions

Sources

1. German Society for Endocrinology (lead organization): Diagnosis and treatment of polycystic ovary syndrome (PCOS), AWMF registration number 089-004, S2k guideline, version 1.1, as of June 2025, valid until June 2030 – register.awmf.org
2. Patient guideline for AWMF registration number 089-004: Diagnosis and treatment of polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS), document dated June 2026 – register.awmf.org
3. World Health Organization: Polycystic ovary syndrome, Fact Sheet, as of 22 January 2026 – who.int

The verbatim quotations regarding the diagnostic criteria (Recommendation 1.2.1), menstrual cycle disorders (1.2.8), AMH (1.2.11 and 1.2.12), and abnormal uterine bleeding (2.7.1) are taken from Source [1], as are the laboratory parameters, differential diagnostics, and the recommendations 1.1.1 and 1.2.4 to 1.2.6 reproduced in substance. The 2003 Rotterdam Consensus, published in 2004 in Human Reproduction, is documented in the bibliography of [1]. The international renaming in May 2026 and the plain-language version of the criteria are taken from [2]. The prevalence, proportion of undiagnosed cases, symptom list, statement regarding ovarian cysts, and connection with the uterine lining are taken from [3]. Information on price and biomarkers comes from the mybody®x product page, accessed on 29 August 2026. All sources were accessed and reviewed on 29 August 2026.

mybody®x Editorial & Expert Team

Women's health Hormonal health Blood analysis interpretation Laboratory diagnostics

This article was created by the mybody®x editorial and expert team. The team combines laboratory diagnostics, nutritional science, and the interpretation of blood analyses. Everyone who contributes to it is listed on the authors page.

Published on 30 August 2026 · Last updated on 30 August 2026

The content is for general information and does not replace medical advice, diagnosis, or treatment. Reference ranges depend on the laboratory, method, and age—the information on your report is always authoritative.